Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

- PMLiVE

AbbVie pays $595m upfront for Boehringer psoriasis drug

Says BI 655066 has the potential to become a ‘best-in-class’ treatment

- PMLiVE

FDA clears Imbruvica as chemo alternative for first-line CLL

Johnson & Johnson/AbbVie's first-in-class drug now approved for all CLL patients

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

Biogen targets ‘lost to follow-up’ patients in MS campaign

Biotech company's 1MSg initiative will provide a range of educational materials

EU flag

CHMP backs orphan drugs Uptravi and Coagadex

EMA advisors set Actelion and Bio Products therapies on path to European approval

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

- PMLiVE

Hints of Humira slowdown weigh on AbbVie

Shares decline on Q4 results, but the biologic is still the world's best-selling medicine

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

FDA verdict on Amgen’s Humira biosimilar due in September

Begins review the version of AbbVie's big-selling anti-inflammatory drug

- PMLiVE

Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

He takes up a seat on the company's board of directors

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links